trial

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

NCTId NCT02535923
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 47 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2021-04-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
47 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2018-03-01
Primary completion
2021-04-20
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
Cognitive Behavioral Therapy-InsomniaHealth and Wellness

Sponsors

VA Office of Research and DevelopmentLead Sponsor
VA Maryland Health Care SystemCollaborator

Investigators

1
Elizabeth A. Klingaman, PhDPrincipal Investigator

Sites

1 total
Baltimore, United States

Facts & assertions

4 sourced
Enrollment
47
Phase
NA
Primary Completion Date
2021-04-20
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Behavioral Therapy-Insomnia
drug
Health and Wellness
drug
lead_sponsor
VA Office of Research and Development
company
collaborator
VA Maryland Health Care System
company
indication
Sleep Initiation and Maintenance Disorders
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Elizabeth A. Klingaman, PhD
person